CVS Group Revenue Rises 5.9% to £710 Million, Launches £50 Million Buyback
CVS Group reported revenue up 5.9% to £710 million with stable margins and strong growth in Australia, alongside a new £50 million share buyback.
You are viewing a historical snapshot of United Kingdom (London Stock Exchange). These figures are a preview to show what TradeTidings covers. Live, continuously updated United Kingdom sentiment and stock impact is a Pro feature.
Get live United Kingdom data with ProOver the last 90 days, Medical Equipment & Services shows 2 positive, 4 neutral and 0 negative news signals across its constituents. The auto-generated sector insight (top drivers with direction + rationale) appears here once the analysis worker has processed enough items.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
How news sentiment on the Medical Equipment & Services sector has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
The most recent stories affecting Medical Equipment & Services, across all of our coverage.
CVS Group reported revenue up 5.9% to £710 million with stable margins and strong growth in Australia, alongside a new £50 million share buyback.
REG - American Century Inv Spire Healthcare Grp - Form 8.3 - Spire Healthcare Group plc
London Deal Activity Keeps Gold Stocks In Focus As Fresnillo (LSE:FRES) Sets The Tone
Convatec has confirmed its chief financial officer is leaving as the medical products group reports half-year results broadly in line with expectations.
Spire Healthcare's takeover offer deadline has been pushed back again, keeping the private hospital operator's shares in an extended period of bid speculation.
European activist investor Cevian Capital has increased its voting stake in Smith & Nephew to 13.206621%, as disclosed in a TR-1 regulatory filing, strengthening its position as a major influence on the medical technology company.